176 related articles for article (PubMed ID: 20380282)
1. Nonmyeloablative conditioning regimens and bone marrow transplantation--some contemporary aspects.
Gocheva LB
Folia Med (Plovdiv); 2010; 52(1):12-7. PubMed ID: 20380282
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. [Homing characteristics of graft cells in leukemia mice after allogenic bone marrow transplantation with different conditioning regimens].
Chen CP; Chen ZZ; Huang HF; Cai XY; He HX; Wu ZC; Luo XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):137-41. PubMed ID: 22391184
[TBL] [Abstract][Full Text] [Related]
4. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Georges GE; Storb R
Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals.
Slavin S; Or R; Aker M; Shapira MY; Panigrahi S; Symeonidis A; Cividalli G; Nagler A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S79-84. PubMed ID: 11587373
[TBL] [Abstract][Full Text] [Related]
7. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
8. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Slavin S; Nagler A; Aker M; Shapira MY; Cividalli G; Or R
Rev Clin Exp Hematol; 2001 Jun; 5(2):135-46. PubMed ID: 11486652
[TBL] [Abstract][Full Text] [Related]
9. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease.
Miralbell R; Bieri S; Mermillod B; Helg C; Sancho G; Pastoors B; Keller A; Kurtz JM; Chapuis B
J Clin Oncol; 1996 Feb; 14(2):579-85. PubMed ID: 8636774
[TBL] [Abstract][Full Text] [Related]
10. Long-term complications of total body irradiation in adults.
Thomas O; Mahé M; Campion L; Bourdin S; Milpied N; Brunet G; Lisbona A; Le Mevel A; Moreau P; Harousseau J; Cuillière J
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):125-31. PubMed ID: 11163505
[TBL] [Abstract][Full Text] [Related]
11. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
12. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
[TBL] [Abstract][Full Text] [Related]
13. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.
Slavin S; Nagler A; Shapira MY; Aker M; Gabriel C; Or R
J Clin Immunol; 2002 Mar; 22(2):64-9. PubMed ID: 11998894
[TBL] [Abstract][Full Text] [Related]
14. Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.
Yang Y; Jorstad NL; Shiao C; Cherne MK; Khademi SB; Montine KS; Montine TJ; Keene CD
Exp Mol Pathol; 2013 Aug; 95(1):7-17. PubMed ID: 23567123
[TBL] [Abstract][Full Text] [Related]
15. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
16. Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review.
Paix A; Antoni D; Waissi W; Ledoux MP; Bilger K; Fornecker L; Noel G
Crit Rev Oncol Hematol; 2018 Mar; 123():138-148. PubMed ID: 29482775
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fractionated total body irradiation and dose rate on cataractogenesis in bone marrow transplantation.
Beyzadeoglu M; Dirican B; Oysul K; Arpaci F; Pak Y
Haematologia (Budap); 2002; 32(1):25-30. PubMed ID: 12243552
[TBL] [Abstract][Full Text] [Related]
20. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
